PharmiWeb.com - Global Pharma News & Resources
29-Aug-2019

MeVis Medical Solutions AG: MeVis publishes figures for the first nine months of fiscal 2018/2019

DGAP-News: MeVis Medical Solutions AG / Key word(s): Interim Report/9 Month figures

29.08.2019 / 16:00
The issuer is solely responsible for the content of this announcement.


Slight increase in revenues with stable costs

  • Revenues at EUR 4.4 million approximately 12 % above previous year's level
  • EBIT of EUR 5.4 million in the first nine months (previous year: EUR 4.4 million)
  • EBIT margin increased slightly to 43 % (previous year: 37 %)
  • Profit after tax of EUR 5.8 million (previous year: EUR 5.1 million)

Bremen, August 29, 2019 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, announces the results for the third quarter and first nine months of fiscal year 2018/2019 (reporting period October 1, 2018 to June 30, 2019).

Revenues in the third quarter of fiscal year 2018/2019 amounted to EUR 4,350 k, about 12 % above the previous year's level (EUR 3,900 k). License business increased by 25 % in the third quarter to EUR 1,239 k (prev. year: EUR 995 k), and the maintenance business by 12 % to EUR 1,822 k (prev. year: EUR 1,632 k) compared to the previous year's period. The service business increased from EUR 1,270 k in the previous year's period to EUR 1,289 k.

Revenues in the first nine months thus amounted to EUR 12,594 k (prev. year: EUR 12,133 k) and were allocated to the segments Digital Mammography with EUR 7,135 k (prev. year: EUR 8,192 k), Development Services with EUR 3,060 k (prev. year: EUR 1,583 k) and Other Operating Activities with EUR 2,399 k (prev. year: EUR 2,358 k). With a share of 57 % (prev. year: 68 %), the Digital Mammography segment continued to be the main source of revenues.

EBIT (Earnings before financial result and taxes) amounted to EUR 5,376 k in the reporting period (prev. year: EUR 4,440 k). At 43 %, the EBIT margin improved compared with a previous year's value of 37 %.

The financial result declined significantly in the reporting period to EUR 390 k (prev. year: EUR 685 k). The change compared with the previous year is due to the development of the balance of income and expenses from exchange rate differences of EUR 494 k (prev. year: EUR 120 k) and the deterioration in the result of the 51 % share in MeVis BreastCare GmbH & Co. KG of EUR -216 k (prev. year: EUR 461 k), which is recognized at equity and interest income in the amount of EUR 127 k (prev. year: EUR 117 k).

Net profit after taxes therefore amounted to EUR 5,766 k (prev. year: EUR 5,122 k), corresponding with undiluted earnings per share of EUR 3.17 (prev. year: EUR 2.81).

************************************************************************

Contact:

Kirchhoff, Marcus / CEO

29.08.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany
Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 865657

 
End of News DGAP News Service

Editor Details

Last Updated: 29-Aug-2019